top of page

A Warm Congratulations to Dr. Laurence Hurley

Updated: Mar 28, 2022

We congratulate Reglagene's Chief Scientific Officer Dr. Laurence Hurley for the granting of FDA Fast Track status for Pidnarulex, the only DNA quadruplex-targeting therapy that is active in human clinical trials. Pidnarulex is for ovarian and breast cancer patients presenting as BRCA1/2 or PALB2 positive. Dr. Hurley was the CSO at Cylene during the preclinical development of Pidnarulex. It is his second quadruplex therapy to reach clinical testing. Dr. Hurley won't stop his contributions to cancer treatments there and is actively working on developing a new brain cancer therapy with the Reglagene team!

Recent Posts

See All

Reglagene has been selected as one of 16 companies for the AZ Inno Madness Competition! Please help us become the 2023 Inno Madness Champion by clicking the link on this post and voting for Reglagene.

bottom of page